At 52 weeks after transplantation, we evaluated the efficacy as following: OCT-based foveal retinal thickness, subretinal fluid, and retinal edema, retinal sensitivity (multifocal ERG, microperimetry), visual acuity (BCVA), dye leakage from CNV by FA, time to need for anti-VEGF treatment, and change in QOL (VFQ-25 scores). The gene discussed is VEGFA; the disease is retinitis.